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ABSTRACT
Epstein Barr Virus (EBV) related Nasopharyngeal Carcinoma (NPC), is an highly 
chemo- and radiosensitive endemic malignancy in southeast Asia. More than one 
third of locally advanced cases relapse after curative treatment, especially because of 
bone, liver and lung metastases. Lymphocyte sub-populations favour EBV-associated 
carcinogenesis and tumour progression and several strategies aim to reverse this 
phenomenon. Receptor activator of NF-kB (RANK) and its Ligand (RANKL), key 
regulator of bone metabolisms, are expressed in several malignancies and tumor-
infiltrating Tregs. We collected 17 paired FFPE specimen of primary and metachronous 
metastatic or regionally relapsed EBV related NPC and evaluated RANK expression by 
immunohistochemistry. All primary tumour specimens resulted not evaluable whereas 
all metastatic specimens, regardless of sites, showed high RANK IHC expression in 
the tumor with no staining in normal surrounding tissues. This observation deserves 
further clarifications and could open the way to trials testing the hypotesis that 
targeting the RANK/RANKL pathway with denosumab, an already available, clinically 
approved monoclonal antibody for metastatic bone lesions, might restore proper anti-
tumor immune response in NPC metastatic patients.
INTRODUCTION
Epstein Barr Virus (EBV) related Nasopharyngeal 
Carcinoma (NPC), while rare in most of the world, is 
an endemic malignancy in southeast Asia [1]. Despite 
being highly chemo- and radiosensitive [2], more than 
one third of locally advanced cases relapse after curative 
treatment, especially because of bone, liver and lung 
metastases [3, 4].
Althought NPC express viral antigens (e.g. LMP1 
and EBNA) [5], as in many other virus related tumors the 
immune system does not play an active role contrasting 
tumor growth and spread. For instance, there is evidence 
that lymphocyte sub-populations favour EBV-associated 
carcinogenesis and tumour progression [6]. Several 
strategies aim to reverse this phenomenon, such as 
restoring CD8+ T cell response via Tregs depletion to 
recreate an effective antitumor immunologic environment 
[7] or EBV-targeted cell therapy with autologous virus-
specific cytotoxic T lymphocytes [8].
Receptor activator of NF-kB (RANK) and 
its Ligand (RANKL) are key regulators of bone 
metabolisms, especially in the metastatic nice, where 
they interact with the immune microenvironment [9–11]. 
In several malignancies, such as breast, prostate cancer 
and osteosarcoma, RANK/RANKL expression has been 
found on both primary and metastatic cells [12–15], as 
well as in tumor-infiltrating Tregs, known for inhibiting 
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antitumoral immunity [16–17]. Furthermore, in a non-
cancer context, it has been reported that RANKL and 
RANK signals are implicated in Treg cell expansion 
[18, 19].
All these premeses lead to the hypothesis that 
targeting the RANK/RANKL pathway with denosumab, 
an already available, clinically approved monoclonal 
antibody for metastatic bone lesions, might restore proper 
anti-tumor immune response in NPC metastatic patients. 
In order to provide data supporting this hypothesis, 
we evaluated whether EBV related NPC primary and 
metastatic tissue present RANK expression.
RESULTS
Primary lesions analysed with RANK IHC showed 
strong background staining due to the lymphatic infiltrate 
present in the specimens that prevented the differential 
evaluation of the proper tumor staining. In order to 
evidentiate the lymphatic infiltrate, double staining 
for pooled CD3/CD20 and RANK was performed on 
NPC primary and metastatic lesion. Furthermore, we 
performed the same double staining on primary and 
nodal breast cancer lesion to provide a positive control. 
Nevertheless, aspecific RANK staining characterized the 
NPC spacimens (Figure 1), with uncertian resultes despite 
several attempts with different technical approach.
Specimens from nodal or metastatic cases had the 
following distributions: neck or metastatic nodes 7/19 
(37%); liver 5/19 (26%); lung 3/19 (16%); bone 2/19 
(10,5%); soft tissue 2/19 (10,5%) (Table 1). Two cases 
resulted not evaluable due to tissue necrosis or strong 
background staining from nodes lymphocytes. All other 
metastatic specimens, regardless of sites, showed high 
RANK IHC expression in the tumor with no staining in 
normal surrounding tissues (Figures 2-4).
DISCUSSION
We documented RANK expression by NPC 
metastatic tissue via IHC. This observation deserves 
further clarifications. An area worth investigation would 
be the possibility to determine RANK expression in 
primary lesion of localised disease at presentation and the 
correlation with prognosis. Indeed, this evaluatoin might 
lead to the identification of RANK as a possible marker of 
more aggressive disease, highlighting the implication of 
RANK pathway in disease progression and the metastatic 
Table 1: Spacimens distribution and staining results
Case # REC/MTS Tissue Analysed Rank IHC
1 REC NODE POS
2 REC NODE POS
3 REC NODE POS
4 REC NODE NOT EVALUABLE*
5 MTS NODE NOT EVALUABLE **
6 MTS NODE POS
7 REC NODE POS
8 REC LIVER POS
9 MTS LIVER POS
10 MTS LIVER POS
11 MTS LIVER POS
12 MTS LIVER POS
13 REC NECK SOFT TISSUE POS
14 REC NECK SOFT TISSUE POS
15 MTS LUNG POS
16 MTS LUNG POS
17 MTS LUNG POS
* too much background staining from lymphoid infiltrate; ** necrosis.
Oncotarget96186www.impactjournals.com/oncotarget
Figure 1: (A-B) RANK (red arrows) and CD3/CD20 (black arrows) double staining of primary nasopharyngheal carcionoma. RANK 
expression is evident in normal nasopharyngeal cells while tumor cells, surrounded by lymphoid infiltrate, present with weak stining.
Figure 2: (A-B) H&E of liver biopsy showing NPC localization. (C-D) RANK IHC; positive areas of RANK expression overlaps with 
NPC cells (black arrows), while Kupfer cells (red arrow) in normal liver tissue represents positive internal control.
process. Primary lesion evaluation could also beter select 
a population with locoregionally advanced neoplasia who 
would benefit from adjuvant treatment.
We encountered difficulties in RANK determination 
on primary lesion, and this represents a limitation of the 
present study. We addressed this issue by performing a 
double staining to differentiate the tumor and the lymphoid 
infiltrate, with equivocal results.
Although the present study does not throughtly 
explore the relationship between the immune context 
and RANK expression by nasopharyngeal carcinoma, 
we consider safe to assume that the already known links 
between RANK/RANKL pathway and Treg in neoplastic 
context can be extended also to nasopharyngeal pathology, 
given the established role of Treg in NPC tumorogenesis 
and progression [24–26] and our newly highlighted 
connection between NPC and RANK.
Our results are consistent with other observation in 
different pathology. Indeed, breast and prostate cancer, 
as well as osteosarcoma, has shown RANK/RANKL 
expression on both primary and metastatic cells [2, 3]. 
Furthermore, our results appears to be solid, even on 
a small sample size, given the 100% positive RANK 
staining on evaluable samples.
Lastly, the greatest implication of our observation 
is the availability of a safe and already approved drug to 
target RANK/RANKL pathway, with potential clinical 
benefit behind bone tournover. Our early results could 
open the way to trials aimed at reinforcing immunological 
response against the tumor through the blockage of Tregs 
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regulated by RANKL, providing a clinical benefit as 
reported in other diseases [20–23]. In light of the data 
recently published in melanoma regarding the potential 
synergistic effect of anti-CTLA4 and anti-RANKL drugs 
described in preclinical model [24], our observation 
could open the possibility for a clinical trial invastigatig 
the combination of immunotherapeutic agents plus anti-
RANKL drug also in metastatic nasopharyngeal cancer. 
Early clinical data have already shown that checkpoint 
inhibition like pembrolizumab provide benefits in a subset 
of metastatic NPC. Therefore, combining more immune-
modulating agents might prove to be a useful, novel 
strategies.
In conclusion, we consider that these simple but 
thrustable observations could offer a strategy for unlocking 
anti tumor immunity, providing a possible new treatment 
opportunity in virally-driven NPC patients.
Figure 4: H&E (A-B) and RANK positive staining (C-D) of NPC lung metastasis.
Figure 3: (A-B) H&E of lymph node metastasis of NPC; (C-D) corresponding RANK staining (black arrows); white cells provide the 
positive internal control in the context of neoplastic island (red arrow).
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MATERIALS AND METHODS
We conducted a retrospective analysis collecting 
17 paired FFPE specimen of primary and metachronous 
metastatic or regionally relapsed EBV-related NPC treated 
in our Institution.
Rank was identified through samples fixed in 4% 
neutral buffered formaldehyde. Representative tumor 
blocks were sectioned at 3μ thickness. IHC was performed 
by the EnVision FLEX+, mouse, hight pH (Link) 
method (Dako Denmark A/S Produktionsvej 42 DK-
2600 Glostrup) with Dako Autostainer Link48. A mouse 
monoclonal antibody against RANK protein (clone 80707, 
R&D Systems, Inc., Minneapolis, MN) was used at a 
concentration of 25 μg/ml. 3-3’-Diaminobenzidine (DAB) 
was used for color development and Mayer’s hematoxylin 
was used for counterstaining.
In order to address the differential evaluation of 
RANK staining in primary lesions and lymphatic infiltrate, 
we selected two NPC cases as well as two breast cancer 
cases as positive control. On these saples, double staining 
for pooled CD3/CD20 and RANK was performed on 
NPC and breast cancer tissue to evidentiate the lymphoid 
infiltrate (CD3/CD20 Dako Denmark A/S Produktionsvej 
42 DK-2600 Glostrup). 3-3’-Diaminobenzidine (DAB) 
was used for CD3/CD20 color development, warp 
red Chromogen Kit for RANK stainig and Mayer’s 
hematoxylin was used for counterstaining.
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